DK1602370T3 - Synergistiske kombinationer omfattende en renininhibitor til hjerte-kredslöbs-sygdomme - Google Patents

Synergistiske kombinationer omfattende en renininhibitor til hjerte-kredslöbs-sygdomme

Info

Publication number
DK1602370T3
DK1602370T3 DK05015603T DK05015603T DK1602370T3 DK 1602370 T3 DK1602370 T3 DK 1602370T3 DK 05015603 T DK05015603 T DK 05015603T DK 05015603 T DK05015603 T DK 05015603T DK 1602370 T3 DK1602370 T3 DK 1602370T3
Authority
DK
Denmark
Prior art keywords
renin inhibitor
cardiovascular disease
synergistic combinations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
DK05015603T
Other languages
Danish (da)
English (en)
Inventor
Randy Lee Webb
William Hewitt
Daniel Lucius Vasella
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1602370(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1602370T3 publication Critical patent/DK1602370T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
DK05015603T 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til hjerte-kredslöbs-sygdomme DK1602370T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0028151A GB0028151D0 (en) 2000-11-17 2000-11-17 Combination of organic compounds
PCT/EP2001/013241 WO2002040007A1 (en) 2000-11-17 2001-11-15 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Publications (1)

Publication Number Publication Date
DK1602370T3 true DK1602370T3 (da) 2008-09-22

Family

ID=9903412

Family Applications (3)

Application Number Title Priority Date Filing Date
DK05015603T DK1602370T3 (da) 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til hjerte-kredslöbs-sygdomme
DK08002401T DK1915993T3 (da) 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til hjertekarsygdomme
DK01996377T DK1341533T3 (da) 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til cardiovaskulære sygdomme

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK08002401T DK1915993T3 (da) 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til hjertekarsygdomme
DK01996377T DK1341533T3 (da) 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til cardiovaskulære sygdomme

Country Status (31)

Country Link
US (4) US8168616B1 (cs)
EP (7) EP1930000A1 (cs)
JP (6) JP2004513920A (cs)
KR (6) KR20100114904A (cs)
CN (4) CN101264072A (cs)
AT (2) ATE317692T1 (cs)
AU (2) AU2368002A (cs)
BR (1) BR0115411A (cs)
CA (2) CA2763223A1 (cs)
CY (5) CY1105603T1 (cs)
CZ (2) CZ305341B6 (cs)
DE (3) DE60117295T2 (cs)
DK (3) DK1602370T3 (cs)
EC (1) ECSP034603A (cs)
ES (4) ES2429292T3 (cs)
GB (1) GB0028151D0 (cs)
HU (2) HU230882B1 (cs)
IL (3) IL155707A (cs)
LU (2) LU91563I2 (cs)
MX (1) MXPA03004358A (cs)
NL (2) NL300385I1 (cs)
NO (2) NO334002B1 (cs)
NZ (6) NZ550897A (cs)
PL (3) PL400915A1 (cs)
PT (3) PT1915993E (cs)
RU (2) RU2310443C2 (cs)
SG (1) SG135969A1 (cs)
SI (3) SI1341533T1 (cs)
SK (1) SK287881B6 (cs)
WO (1) WO2002040007A1 (cs)
ZA (1) ZA200303497B (cs)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266836A1 (en) * 2001-10-18 2004-12-30 Peter Buhlmayer Organic compounds
ATE520417T1 (de) 2002-05-17 2011-09-15 Novartis Pharma Gmbh Pharmazeutische zusammensetzung enthaltend einen renin inhibitor, einen kalziumkanalblocker und ein diuretikum
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
EP1517682B1 (en) * 2002-06-28 2006-11-02 Speedel Pharma AG Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
EP1531879A1 (en) * 2002-06-28 2005-05-25 Novartis AG Use of organic compounds
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
CN102260188A (zh) * 2003-11-26 2011-11-30 诺瓦提斯公司 有机化合物
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
AR047445A1 (es) * 2004-01-23 2006-01-18 Speedel Experimenta Ag Compuestos derivados de amino alcohol con actividad inhibidora de la renina y su uso en composiciones farmaceuticas.
AR047447A1 (es) * 2004-01-23 2006-01-18 Speedel Experimenta Ag Compuestos derivados de amino alcohol con actividad inhibidora de la renina y su uso en composiciones farmaceuticas.
TW200529837A (en) 2004-01-23 2005-09-16 Speedel Experimenta Ag Organic compounds
PE20060075A1 (es) 2004-03-17 2006-03-20 Novartis Ag Composiciones farmaceuticas de alisciren
JP2007529459A (ja) * 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 治療に置けるレニン阻害剤の使用
BRPI0508969A (pt) * 2004-03-19 2007-08-21 Speedel Experimenta Ag compostos orgánicos
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
AU2005294318A1 (en) * 2004-10-08 2006-04-20 Novartis Ag Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
EP1897879A3 (en) 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
US20090247582A1 (en) * 2005-04-27 2009-10-01 Randy Lee Webb Methods of treating atherosclerosis
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
CN1732952B (zh) * 2005-09-02 2010-04-07 姚俊华 一种治疗高血压的复方分散片
EP1930008A1 (en) * 2005-09-28 2008-06-11 Teva Pharmaceutical Industries Ltd Sable composition of benazepril hydrochloride
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
AU2006311723A1 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CA2646438A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
CN101583355A (zh) * 2006-12-15 2009-11-18 诺瓦提斯公司 用于在肥胖患者中预防和治疗高血压的肾素抑制剂
US20080194626A1 (en) * 2007-02-14 2008-08-14 Gorczynski Richard J Antihypertensive drug combination
CL2008002829A1 (es) * 2007-09-28 2009-06-26 Novartis Ag Combinacion farmaceutica de dosis oral fija que comprende aliskireno y valsartan; uso de la combinacion para tratar hipertension, angina, infarto al miocardio, arterioscleosis, nefropatia diabetica, insuficiencia renal, entre otras; metodos de preparacion de la combinacion en forma de bicapa y en forma se tableta sobre encapsulada.
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
KR101164300B1 (ko) 2008-02-22 2012-07-09 한올바이오파마주식회사 약제학적 제제
EP2275093A2 (en) 2008-04-10 2011-01-19 HanAll Biopharma Co., Ltd. Pharmaceutical formulation
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
MX2011009846A (es) 2009-03-20 2011-09-29 Novartis Ag Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
EP2704706A1 (en) 2011-05-06 2014-03-12 Artskin D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
RU2483750C1 (ru) * 2012-03-19 2013-06-10 Общество с ограниченной ответственностью "СупраГен" Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st
JP2015516441A (ja) * 2012-05-18 2015-06-11 ルオダ ファーマ ピーティーワイ リミテッド 液体配合剤
RU2554815C1 (ru) * 2014-06-18 2015-06-27 Общество с ограниченной ответственностью "Нанолек" Гипотензивное средство
BR112017001758A2 (pt) 2014-07-30 2017-11-21 Merck Patent Gmbh álcoois polivinílicos diretamente compressíveis
CN109890389B (zh) * 2016-10-27 2022-07-01 达米安制药股份公司 醛固酮合酶抑制剂

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022978A1 (en) 1995-01-27 1996-08-01 Rhone Poulenc Rorer Limited Substituted phenyl compounds as endothelin antagonists
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
FI77669C (fi) 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4782043A (en) 1983-06-15 1988-11-01 Merck & Co., Inc. Renin inhibitors containing a C-terminal amide cycle
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4812442A (en) 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
SE8802428D0 (sv) * 1988-06-28 1988-06-28 Haessle Ab New compounds
US5268374A (en) 1988-10-04 1993-12-07 Abbott Laboratories Non-peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
EP0955294B1 (en) 1989-06-14 2003-09-24 Smithkline Beecham Corporation Imidazolyl-alkenoic acid
EP0438311A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Di- and tripeptide renin inhibitors
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
RO115786B1 (ro) * 1990-05-11 2000-06-30 Pfizer Compozitie pentru scaderea presiunii sangelui sau tratarea atacurilor cardiace congestive, la mamifere, si metoda de tratament
WO1992000972A1 (en) 1990-07-11 1992-01-23 Abbott Laboratories Renin inhibiting compounds
WO1992003429A1 (en) * 1990-08-15 1992-03-05 Abbott Laboratories Renin inhibitors
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
EP0565634B1 (en) 1990-12-14 1999-03-17 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
AU1256692A (en) 1991-02-06 1992-09-07 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
CA2061607C (en) 1991-02-21 1999-01-19 Hiroaki Yanagisawa 1-biphenylimidazole derivatives, their preparation and their therapeutic use
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
TW226375B (cs) 1991-10-24 1994-07-11 American Home Prod
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
CN1129428C (zh) 1993-04-27 2003-12-03 史密丝克莱恩比彻姆公司 内皮素受体拮抗剂
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
EP0634175B1 (de) * 1993-07-15 2001-01-10 F. Hoffmann-La Roche Ag Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
CN1049219C (zh) 1993-08-18 2000-02-09 万有制药株式会社 具有内皮素拮抗活性的芳香杂环并环戊烯衍生物
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
CA2128199C (en) 1994-07-15 1997-02-04 Bernard Charles Sherman Stable solid pharmaceutical compositions containing enalapril maleate
AU711832B2 (en) 1994-08-19 1999-10-21 Abbvie Bahamas Ltd. Endothelin antagonists
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (cs) 1994-12-20 1997-08-21 Hoffmann La Roche
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
RU2172735C2 (ru) 1995-12-20 2001-08-27 Яманоути Фармасьютикал Ко., Лтд. Арилэтенсульфонамидные производные и фармацевтическая композиция
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
WO1997027314A1 (fr) 1996-01-23 1997-07-31 Shionogi & Co., Ltd. Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse
CZ296098A3 (cs) 1996-04-04 1999-06-16 Banyu Pharmaceutical Co., Ltd. Způsob léčby srdečního selhání antagonisty endothelinu
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
WO1999065500A1 (en) * 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
EP1098634A4 (en) 1998-07-20 2006-10-25 Smithkline Beecham Corp EPROSARTAN CONTAINING MORE EFFECTIVE FORMULATIONS IN ORAL SOLID PHARMACEUTICAL FORM
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
WO2000056403A1 (en) * 1999-03-19 2000-09-28 The Brigham And Women's Hospital, Inc. UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
ATE370738T1 (de) 1999-11-09 2007-09-15 Pharmacia Corp Verwendung von eplerenon zur behandlung von restenose
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
ATE520417T1 (de) 2002-05-17 2011-09-15 Novartis Pharma Gmbh Pharmazeutische zusammensetzung enthaltend einen renin inhibitor, einen kalziumkanalblocker und ein diuretikum
WO2004059136A1 (de) 2002-12-31 2004-07-15 Volkswagen Aktiengesellschaft Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffähige verbrennungskraftmaschine

Also Published As

Publication number Publication date
ES2308347T3 (es) 2008-12-01
LU91563I2 (fr) 2009-07-06
US20120004312A1 (en) 2012-01-05
ATE397445T1 (de) 2008-06-15
AU2002223680B2 (en) 2005-04-07
CA2763223A1 (en) 2002-05-23
KR101258365B1 (ko) 2013-04-30
CY2009005I1 (el) 2012-01-25
HUP0301841A2 (hu) 2003-09-29
RU2310443C2 (ru) 2007-11-20
LU92315I2 (fr) 2014-01-27
SI1915993T1 (sl) 2013-10-30
BR0115411A (pt) 2004-08-17
CY1114829T1 (el) 2015-11-04
DE60134349D1 (de) 2008-07-17
ATE317692T1 (de) 2006-03-15
EP1930000A1 (en) 2008-06-11
CY2009005I2 (el) 2012-01-25
CA2428647A1 (en) 2002-05-23
NO2013019I2 (no) 2013-12-17
EP1341533A1 (en) 2003-09-10
EP1915993B1 (en) 2013-07-10
NO20032233D0 (no) 2003-05-16
MXPA03004358A (es) 2003-08-19
JP6603757B2 (ja) 2019-11-06
KR20100114904A (ko) 2010-10-26
DE60117295T2 (de) 2006-08-17
EP1915993A1 (en) 2008-04-30
JP2018131465A (ja) 2018-08-23
EP2305233A1 (en) 2011-04-06
SI1341533T1 (sl) 2006-08-31
CN101264072A (zh) 2008-09-17
US8618174B2 (en) 2013-12-31
NO2013019I1 (no) 2014-06-02
JP6577994B2 (ja) 2019-09-18
JP2004513920A (ja) 2004-05-13
EP1602370A3 (en) 2005-12-14
EP1602370A2 (en) 2005-12-07
HUP0301841A3 (en) 2010-07-28
HK1115544A1 (en) 2008-12-05
KR20110063596A (ko) 2011-06-10
KR20080096715A (ko) 2008-10-31
NZ550897A (en) 2008-03-28
DK1915993T3 (da) 2013-10-14
ES2429292T3 (es) 2013-11-14
IL212075A0 (en) 2011-06-30
JP6089278B2 (ja) 2017-03-08
JP6373931B2 (ja) 2018-08-15
RU2346703C2 (ru) 2009-02-20
NO334002B1 (no) 2013-11-11
CZ305341B6 (cs) 2015-08-05
CY2013045I1 (el) 2015-11-04
WO2002040007A1 (en) 2002-05-23
CY1108305T1 (el) 2012-01-25
EP1341533B1 (en) 2006-02-15
EP2305232A1 (en) 2011-04-06
ZA200303497B (en) 2004-04-28
EP2305231A1 (en) 2011-04-06
HU1400409D0 (hu) 2003-09-29
KR20080011355A (ko) 2008-02-01
ES2256335T3 (es) 2006-07-16
EP2305232B1 (en) 2019-07-17
NL301005I1 (cs) 2019-09-10
US20120016035A1 (en) 2012-01-19
KR20030051753A (ko) 2003-06-25
CY2013045I2 (el) 2015-11-04
US8168616B1 (en) 2012-05-01
NO20032233L (no) 2003-05-16
HK1089356A1 (en) 2006-12-01
PL361404A1 (en) 2004-10-04
GB0028151D0 (en) 2001-01-03
CN1474690A (zh) 2004-02-11
US9023894B2 (en) 2015-05-05
DE60117295D1 (de) 2006-04-20
NZ550896A (en) 2008-06-30
PT1915993E (pt) 2013-10-14
JP2017019876A (ja) 2017-01-26
NZ525795A (en) 2005-03-24
SK287881B6 (sk) 2012-02-03
PL227576B1 (pl) 2017-12-29
US9023893B2 (en) 2015-05-05
ES2734523T3 (es) 2019-12-10
JP2018030894A (ja) 2018-03-01
CY1105603T1 (el) 2010-07-28
JP2009235107A (ja) 2009-10-15
PL400915A1 (pl) 2012-12-17
IL155707A (en) 2012-02-29
NZ568764A (en) 2009-11-27
NZ537691A (en) 2007-01-26
HU230882B1 (hu) 2018-11-29
RU2006132668A (ru) 2008-03-20
DK1341533T3 (da) 2006-05-08
DE122009000021I1 (de) 2009-08-06
PL400914A1 (pl) 2012-12-17
NL300385I1 (nl) 2009-07-01
SG135969A1 (en) 2007-10-29
EP1602370B1 (en) 2008-06-04
PT1602370E (pt) 2008-09-10
KR101008752B1 (ko) 2011-01-14
NL301005I2 (nl) 2019-10-29
IL212075A (en) 2013-08-29
SI1602370T1 (sl) 2008-10-31
ECSP034603A (es) 2003-06-25
CN100404024C (zh) 2008-07-23
NZ550898A (en) 2008-07-31
IL217847A0 (en) 2012-03-29
SK5842003A3 (en) 2003-11-04
IL155707A0 (en) 2003-11-23
PT1341533E (pt) 2006-06-30
AU2368002A (en) 2002-05-27
KR20080097488A (ko) 2008-11-05
JP2013213061A (ja) 2013-10-17
HK1059212A1 (en) 2004-06-25
CN101264073A (zh) 2008-09-17
CN101091703A (zh) 2007-12-26
CZ299749B6 (cs) 2008-11-12
US20120010295A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
DK1341533T3 (da) Synergistiske kombinationer omfattende en renininhibitor til cardiovaskulære sygdomme
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
RS50485B (sr) Terapeutske kombinacije koje sadrže amplodipin i atorvastatin
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
EP1734041A3 (en) Platelet ADP receptor inhibitors
HUP0400202A3 (en) Imidazolidindion derivatives having metalloproteinase inhibitor effect, their use and pharmaceutical compositions containing them
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
DE60042585D1 (de) 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
FI940568A7 (fi) Anti-inflammatorisina aineina toimivia oksindoli-1-(N-(alkoksikarbonyyli))karboksamideja ja -1-(N-karboksamido)-karboksamideja
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
ITMI931806A0 (it) Composti inibitpri di acil enzima-a-colesterolo-o-acil transferasi ad attivita' terapeutica , loro uso e composizioni farmaceutiche che li contengono
IL136687A0 (en) Pharmaceutical composition for the treatment of multiple sclerosis
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.
RU2000128859A (ru) Способ защиты печени от ксенобиотиков в эксперименте
NO20042153L (no) Piperidin-2-on-derivatforbindelser og farmasoytisk sammensetning omfattende samme som aktiv ingrediens